“Tumor-targeted costimulatory trimerbodies for cancer immunotherapy.”- A brief discussion with Juan Perez Villar, CEO, LeadArtis.

“Tumor-targeted costimulatory trimerbodies for cancer immunotherapy.”-  A brief discussion with Juan Perez Villar, CEO, LeadArtis.

Doctor in Immunology from the Autonomous University of Madrid (Spain), extensive international career in the biopharmaceutical industry at Astellas Inc. and Bristol-Myers Squibb Co. (USA). Experienced R&D leader in immune-oncology (IO). Previously, participated in preclinical development of CD28 biologic modulators for inflammatory conditions, small molecule tyrosine kinase inhibitors and fully human antibodies for advanced solid tumors at Leadartis. He advanced the company from start to capitalize on the immuno-oncology (IO) market. Evaluated and repositioned the platform technology to create IO bispecific antibody dominance and created a proprietary next generation product…

Read More

Héctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”

Héctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”

Héctor’s work has always focused on understanding the molecular pathophysiological mechanisms leading to autoimmunity and cancer development, investigating mechanism of action of newly developed molecules to treat such diseases. He started his career in 2006 when he moved to UT Southwestern Medical Center in Dallas (EEUU), to carry out this thesis in developing novel therapeutic antibodies in murine models of human autoimmune diseases. After obtaining his Ph.D., he combined two postdoctoral grants in Barcelona (Metastasis and Transformation group in Bellvitge Biomedical Research Center) and in Valencia (Autoimmune Pathology Lab in…

Read More

Dr. William Williams of Briacell Therapeutics Corporation talks about Personalized, off-the-shelf cellular immunotherapy for cancer

Dr. William Williams of  Briacell Therapeutics Corporation talks about Personalized, off-the-shelf cellular immunotherapy for cancer

Dr. Williams is the President and CEO of BriaCell Corporation, where he has shepherded Bria-IMT™ into the clinic, established positive proof-of-concept, forged a collaboration with Incyte for novel combinations and coordinated the development of an off-the-shelf personalized approach to cancer immunotherapy. While at Incyte Corporation as Head of Exploratory Development, he brought numerous molecules into the clinic and established proof of concept in several disease areas. At GlaxoSmithKline he worked to bring several molecules into the clinic, ran a biomarker laboratory and spearheaded initiatives to utilize emerging technologies in drug…

Read More

Speaker Inerview with William Williams for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Speaker Inerview with William Williams for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Philadelphia, USA August 10, 2019 – MarketsandMarkets recently interviewed William Williams, President, CEO BriaCell Corporation regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City.  Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. The major advance has been to crack the code of immunosuppression induced by cancer, especially via checkpoint inhibitors such as antibodies to CTLA4 and PD-1/PD-L1.  This has made many tumors amenable to immunotherapy.  However, the generalized nature of…

Read More

Speaker Inerview with Emmanuel Normant for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Speaker Inerview with Emmanuel Normant for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Philadelphia, USA August 09, 2019 – MarketsandMarkets recently interviewed Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Emmanuel Normant is vice president of preclinical sciences at TG Therapeutics, a clinical-stage biotech company focused on hematologic cancers and located in New-York. There, he leads the three early pipeline programs, including a novel irreversible BTK inhibitor, and anti-PD-L1 monoclonal antibody and a bispecific antibody directed against CD19 and CD47. All three assets have entered…

Read More

Speaker Interview With Frank Borriello For 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Speaker Interview With Frank Borriello For 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Philadelphia, USA July 31, 2019 – MarketsandMarkets recently interviewed Frank Borriello, CEO, Alloplex Biotherapeutics, regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. While there have been many advances in the field of cellular therapy in oncology, the common element limiting their adoption will be reproducibility of manufacturing, whether autologous or allogeneic, as well as generalizability across multiple tumor types, whether…

Read More

Emerging 4 Trends – Cancer Immunotherapy Biomarkers

Emerging 4 Trends – Cancer Immunotherapy Biomarkers

Cancer immunotherapy has turned out to be a revolutionary treatment to fight against this largest group of diseases in the world. The artificial stimulation of the immune system enhances the natural ability of the body to fight against cancer. The field on immunotherapy shows a great potential in treating a wide range of types of cancers. Over 8,000 cancer immunotherapy experiments are taking place in clinical trials along with which includes rapid development of biomarkers. The smart and effective immunotherapy is already transforming cancer treatment approach while biomarkers, in addition,…

Read More